Group items tagged

The NHS has secured a deal for 'Pembrolizumab' to treat women with triple-negative breast cancer. Up to 1,600 women a year affected by high risk triple-negative breast cancer are set to benefit from the confidential deal struck by the NHS and the Merck Sharp and Dohme's (MSD), manufacturer of Pembrolizumab. Triple-negative breast cancer affects around 8,000 women a year - accounting for 15% of all breast cancer cases. This will be the 25th breast cancer treatment fast-tracked to patients through funding from the Cancer Drugs Fund and the second treatment for triple negative breast cancer to be introduced this year on the NHS. NHS chief executive, Amanda Pritchard, said: "This is a hugely significant moment for women - the NHS has struck a new deal to roll out a potentially life-saving drug for patients suffering with the most aggressive form of breast cancer that has been traditionally very difficult to treat.

Prostate cancer is the most common cancer among men in the United Kingdom. However, Macmillan revealed that prostate cancer diagnoses were down 29 per cent between 2019 and 2020, meaning men weren't seeing their GPs to begin to get diagnosed. Therefore, it is of utmost importance to spot any symptoms and get checked, as an early diagnosis can help not only increase survival rates, but also offer a more varied choice of treatment options. As community pharmacy teams play a fundamental role in educating men who may be concerned about their health it vital to maximise trusted relationship with patients, and it is crucial that pharmacists have access to the correct resources to direct men to seek prostate cancer guidance. Prostate cancer often affects men who are over the age of 50. Those who are at a higher risk of prostate cancer also include those of African-Caribbean family descent, if there has been a family history of the cancer, and poor weight and diet. However, studies have found that community pharmacists play an important role in delivering programmes to improve levels of physical activity and diet of men with prostate cancer.

A group of drugs commonly used to treat erectile dysfunction may be able to boost the effect of chemotherapy in oesophageal cancer, according to new research funded by Cancer Research UK and the Medical Research Council. The research, published on Tuesday (June 22) in Cell Reports Medicine, found that the drugs, known as PDE5 inhibitors can reverse chemotherapy resistance by targeting cells called cancer-associated fibroblasts (CAFs) residing in the area surrounding the tumour. Although this is early discovery research, PDE5 inhibitors combined with chemotherapy, may be able to shrink some oesophageal tumours more than chemotherapy could alone, tackling chemotherapy resistance, which is one of the major challenges in treating oesophageal cancer. Oesophageal cancer affects the food pipe that connects the mouth to the stomach, and while it is a relatively rare cancer, the UK has one of the higher rates in the world, with 9,300 new oesophageal cancer cases in the UK every year. Resistance to chemotherapy in oesophageal cancer is influenced by the tumour microenvironment, the area that sounds the tumour. This is made up of molecules, blood vessels, and cells such as cancer associated fibroblasts (CAFs), which are important for tumour growth. It feeds the tumour and can act as a protective cloak, preventing treatments like chemotherapy from having an effect.

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer. The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers at Imperial College London. For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility at Hammersmith Hospital. In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of immune checkpoint inhibitor. The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for difficult-to-treat cancers.

Palbace 125 Mg Capsules Suppliers-exporters India , Palbace a 125Mg Capsule is employed within the treatment of carcinoma. It's additionally wont to treat patients with bound varieties of carcinoma (estrogen receptor-positive, human stratum protein receptor 2-negative) that have unfold to alternative organs. it's given in conjunction with secretion malignant tumor therapies. We are leading suppliers & exporters of "Palbace 125Mg" in China, Russia, Hongkong, Bulgaria, Romania, India. We're largest suppliers of Pfizer India medicines & provide you the best price on Palbace 125Mg. The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us. Buy Online Palbace 125Mg Suppliers Price India Palbace 125Mg suppliers India Palbace 125mg Capsules Palbace (known as IBRANCE in other parts of the world) or palbociclib by Pfizer is a cancer drug that interferes with the growth and spread of cancer cells in the body. Description Brand Name: Palbace Generic Name: Palbociclib Strength: 125mg Packing: 21 Capsules in a bottle Form: Tablets Palbace125Mg is generally used in combination with letrozole or fulvestrant (Faslodex) for treating certain types of advanced breast cancer in postmenopausal women. It is also given in combination with another cancer medicine, either letrozole (Femara) or fulvestrant (Faslodex). Palbace is a renamed version of the drug Ibrance for the Indian market. It is verified by the US Food and Drug Administration (FDA). In clinical studies, palbociclib appeared to increase survival time of patients. Palbace comes in capsule form in 125 mg dose. 1 pack has 21 capsules. How Palbace125Mg capsules works ? Palbace 125mg capsule is an anti-cancer medication. It works by busy bodied with a enzyme, a sort of supermolecule within the body that helps management biological process. This stops cancer cells from dividing and growing. It is additionally won't to treat patients with bound kinds of carc

Presently, In the US, around 12% of women develop breast cancer over the course of their lifetime. In Canada, an estimated 26,900 women were expected to be diagnosed with breast cancer in 2019 and breast cancer accounts for nearly 25% of new cases of cancer among Canadian women. Download complete report summary @ http://bit.ly/2vsEa1D

The NHS is going to roll out a revolutionary 30-minute treatment for advanced womb cancer for women across England. The drug, called Dostarlimab, would benefit around 100 women with advanced and often incurable endometrial cancer every year after the NHS agreed early access to the treatment through the Cancer Drugs Fund. It works by attaching to a specific protein on the surface of the cancer cells, helping the immune system to detect and attack it. The treatment takes just 30 minutes to administer through the blood stream every three weeks over a 12-week period. The move is in line with the NHS Long Term Plan which aims to provide the latest cutting-edge treatments and therapies for patients.

What are the sign & symptoms of colon cancer, colon cancer kya Hota hai, how to prevent colon cancer naturally, colon cancer treatment, etc? Know in details about colon cancer, Watch this video by Dr. Priya Tiwari, Senior Consultant - Medical Oncologist, a colon cancer specialist, colon cancer doctor & cancer specialist in Gurgaon, Haryana, Delhi, and UP.

ओरल कैविटी कैंसर क्या है? भारत में ओरल कैविटी कैंसर क्यों आम है? what is oral cancer, oral cancer treatment, oral cancer diagnosis, oral cancer kya hei, kaise pehchane muh ka cancer, oral cancer treatment in gurgaon, oral cancer treatment in haryana

Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. Know what is breast cancer, symptoms of breast cancer, breast cancer symptoms in Hindi, treatment for breast cancer, etc. Watch this video by Dr. Priya Tiwari, Senior Consultant - Medical Oncologist, cancer doctor & cancer specialist in gurugram

The drug, alpelisib, which is the 100th cancer drug that has being fast-tracked to patients under the NHS Cancer Drugs Fund (CDF) will be used in combination with the hormone therapy, fulvestrant, to target the gene that causes fast-growing tumours. Up to 3,000 people a year with a certain type of secondary breast cancer will benefit from the treatment. The approach has contributed to people in England having access to nearly one third more cancer drugs compared to the European average. The drug which is manufactured by pharmaceutical company Novartis, is part of a growing number of precision treatments that target a tumour based on mutations in its DNA and that the NHS is rolling out. John Stewart, NHS National Director for Specialised Commissioning said, "In just over five years, more than 80,000 people have benefitted from earlier access to a range of cancer drugs, with people in England having access to nearly one third more cancer drugs compared to the European average, and this latest innovative new treatment will help up to 3,000 more to live a better quality of life.

The drug, 'durvalumab', can double the overall time someone can survive with an aggressive form of lung cancer from two-and-a-half to five years. It has been approved by the National Institute for Health and Care Excellence (NICE) and the NHS has sealed a deal with manufacturer AstraZeneca to begin rolling it out. The new treatment will be offered to more than 550 patients a year with advanced non-small-cell lung cancer (NSCLC) who have already undergone both chemotherapy and radiotherapy concurrently. NHS said: "The drug can stop the cancer from getting worse for more than two years - significantly longer than treatment with a combination of chemotherapy and radiotherapy, which can only hold the disease at bay for around six months. This increases overall survival time and gives patients more precious moments with their loved ones." Dame Cally Palmer, national cancer director for NHS England, said: "We are resolute in our ambition to fight the devastating effects of cancer and new pioneering treatments like durvalumab are a vital lifeline for people living with cancer - giving them more precious time with family and friends.

Oral cancer is diagnosed in more than a million people each year. It is also known as oral cavity cancer or mouth cancer. The disease manifests itself in the parts of mouth and throat and comes under the category of head and neck cancer. This article talks everything about Oral Cancer Treatment In India, Oral Cancer Hospitals In India & what is the Oral Cancer Costs In India? It covers other popular medical tourism destinations as well.

Alphega Pharmacy Oncology Support Programme allows community pharmacists from six European countries to enhance support and guidance they provide to cancer patients. The programme aims to help upskill pharmacists and their teams to provide more expert advice to patients living with cancer, raising their profile in the community as key healthcare providers. Enhancing knowledge amongst community pharmacists about cancer treatment and its side effects is vital as cancer cases are set to increase if current trends continue. The programme covers practical help topics, such as oral care, nutrition advice and skin, hair and nail care among others, helping patients to get more of the support they need because community pharmacists are easily accessible, rather than needing to book a GP or consultant appointment. With rates of cancer forecast to rise throughout Europe , and cancer patients likely on average to visit hospital less often, community pharmacists are well-placed to look to support cancer patients with managing the side-effects of their treatment.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

AstraZeneca said on Thursday (June 30) that a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery. Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in patients with non-small cell lung cancer, the drugmaker said. The interim result is a boost to the company's oncology efforts - a major area of focus - following disappointing data for Imfinzi earlier in the year in another area of therapy. AstraZeneca added the trial would continue as planned to assess the additional main goal of event-free survival, and the interim data would be shared with health authorities globally. Imfinzi belongs to the immunotherapy class of treatments, which boost the body's defences to fight cancer by using antibodies that block or bind to foreign substances in the body. The treatment generated $2.41 billion in 2021 sales.

NICE has recommended use of tucatinib as an option to treat HER2-positive breast cancer that has spread in people who have already tried 2 or more anti-HER2 treatments. The move is set to benefit around 400 people with advanced breast cancer. Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading. The medicine is taken as two 150 mg tablets twice daily along with anti-cancer medicines trastuzumab and capecitabine. Helen Knight, programme director in the NICE Centre for Health Technology Evaluation, said: "Unfortunately there is no cure for breast cancer that has spread to other parts of the body. There is also a lack of additional anti‑HER2 treatments which can postpone the need for chemotherapy, especially for people whose cancer has spread to their brain because their treatment options are even more limited.

Prostate cancer is the most common cancer among men in the United Kingdom, affecting nearly 50,000 men yearly. Combined with the challenges faced across healthcare during COVID-19, new figures show that prostate cancer accounts for a third of cancers not treated due to the pandemic, with 14,000 'missing patients' believed to have not undergone treatment since April 2020. It is more urgent than ever that men are encouraged to get checked, as any set-backs in diagnosis can reduce the pathways available, in turn affecting health outcomes. Community pharmacy teams play a crucial role in signposting the help available for men who may be concerned about their health. Therefore, it is vital that pharmacy teams have access to the information they need to correctly direct men to seek prostate cancer guidance. By maximising the trusted relationship between patients and their pharmacists, more can be done to identify the warning signs, helping men to get an earlier diagnosis.

Pharmaceutical giant AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday (November 29) as it seeks to build its pipeline of cell-based cancer treatments. Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy and is behind rivals such as Novartis and Gilead. "Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the last three years," said Susan Galbraith, AstraZeneca's executive vice president of oncology research. Cell-based treatments are a relatively new approach to treating cancer, most of which involve drawing the body's own immune cells and processing them in the lab to target and kill cancer cells. Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain proteins on the surface of cancer cells.